TMCnet News

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against The Chemours Company (CC)
[April 01, 2024]

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against The Chemours Company (CC)


Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming May 20, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired The Chemours Company ("Chemours" or the "Company") (NYSE: CC) common stock between February 10, 2023 and February 28, 2024, inclusive (the "Class Period").

If you suffered a loss on your Chemours investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at www.glancylaw.com/cases/The-Chemours-Company-1/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

On February 13, 2024, after the market closed, Chemours disclosed that it was postponing the release of its financial results and conference call related to its fourth quarter and full year 2023. The Company further clarified, stating that it was delaying its results because Chemours is "evaluating its internal control over financial reporting as of December 31, 2023 with respect to maintaining effective controls related to information andcommunications," and because the Company's Audit Committee "needs additional time to complete a related internal review."



On this news, Chemours' stock price fell $3.85, or 12.6%, to close at $26.64 per share on February 14, 2024, thereby injuring investors.

Then, on February 29, 2024, Chemours announced that its CEO, CFO, and Controller had been placed on "administrative leave" pending the completion of an internal review, including reviewing reports made to the Chemours Ethics Hotline. Additionally, the Company delayed its earnings report and disclosed that it is "evaluating one or more potential material weaknesses in its internal control over financial reporting[.]"


On this news, Chemours' stock price fell $9.05, or 31.5%, to close at $19.67 on February 29, 2024, thereby injuring investors further.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) certain of the Company's senior executive officers manipulated Free Cash Flow targets as a means to maximize additional cash and stock incentive compensation applicable to executive officers pursuant to the Company's AIPs and LTIPs; (2) the Company's accounting practices and procedures, including its internal control over financial reporting, were deficient; and (3) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Follow us for updates on LinkedIn, Twitter, or Facebook.

If you purchased or otherwise acquired Chemours common stock during the Class Period, you may move the Court no later than May 20, 2024 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


[ Back To TMCnet.com's Homepage ]